Dr. reddy's announces the re-launch of over-the-counter naproxen sodium tablets usp, 220 mg, store-brand equivalent of aleve® in the u.s. market

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, nseifsc: drreddy, along with its subsidiaries together referred to as “dr. reddy's”) today announced the re-launch of over-the-counter (otc) naproxen sodium tablets usp, 220 mg, the store-brand equivalent of aleve®, in the u.s. market, as approved by the u.s. food and drug administration (usfda). “the re-launch of dr. reddy's naproxen sodium tablets, 220 mg (otc), is an impo
RDY Ratings Summary
RDY Quant Ranking